NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00272948,Pediatric Trial Investigating the Incidence & Outcome of Veno-Occlusive Disease With the Prophylactic Use of Defibrotide,https://clinicaltrials.gov/study/NCT00272948,VOD-DF,COMPLETED,The aim of this trial is to evaluate whether the prophylactic use of Defibrotide (DF) in pediatric patients (age less than 18 years) undergoing stem cell transplantation and who are at high risk of developing hepatic Veno-occlusive Disease (VOD) will have an impact on the incidence and severity of the disease. Patients will be randomly assigned to one of two treatment arms: Those allocated to the Prophylactic Arm will receive the study drug (Defibrotide) from the day of conditioning onwards. Patients allocated to the Control Arm will receive the study drug (Defibrotide) from the day that VOD is diagnosed.,NO,Hepatic Veno-Occlusive Disease,DRUG: Defibrotide|DRUG: Defibrotide|DRUG: Defibrotide,"The primary objective is to evaluate if prophylactic DF has an impact on the incidence of VOD, Day + 30 post HSCT","Occurrence of Multi-System Organ Failure and Survival (all causes of mortality), day +100 post HSCT",,European Society for Blood and Marrow Transplantation,"Jazz Pharmaceuticals|Deutsche Krebshilfe e.V., Bonn (Germany)",ALL,"CHILD, ADULT",PHASE2|PHASE3,360,NETWORK,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,EudraCT Number:2004-000592-33|EBMT-PD-200601,2005-12,2009-01,2009-07,2006-01-09,,2011-06-09,"University Hospital, Graz, Austria|St Anna Kinderspital, Wien, Austria|Inst. Gustave Roussy, Villejuif, France|University Hospital, Dresden, Germany|Klinik Kinder-Onkologie, Düsseldorf, Germany|Johann-Wolfgang Goethe Universität, Frankfurt, Germany|Universitätsspital Eppendorf, Hamburg, Germany|Medical School, Hannover, Germany|University Hospital, Heidelberg, Germany|Kinderklinik, Jena, Germany|Christian-Albrecht -University, Kiel, Germany|Kinderpoliklinik Uni, München, Germany|Poliklinik Kinderheilkunde, Münster, Germany|Universitätsspital, Tübingen, Germany|Our Lady's Hospital for Sick Children, Dublin, Ireland|Schneider Children's MC, Petach-Tikva, Israel|Institute G. Gaslini, Genova, Italy|Ospedale S. Gerardo, Monza, Italy|Clinica di Oncoematologia Pediatrica, Padova, Italy|University Hospital, Utrecht, Netherlands|Sahlgrenska University Hospital, Göteborg, Sweden|University Hospital, Huddinge, Sweden|University Hospital, Lund, Sweden|University Hospital, Uppsala, Sweden|University Children Hospital, Basel, Switzerland|Inselspital, Bern, Switzerland|Hopital Cantonal Universitaire, Geneva, Switzerland|University Hospital, Zürich, Switzerland|Great Ormond Street Hospital, London, United Kingdom|Children's Hospital, Manchester, United Kingdom",
